We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance

Results: 1-10 of 1,514

International Life Sciences Review: Issue 8
  • Morgan Lewis & Bockius LLP
  • USA, Netherlands, China, European Union, France, Global
  • February 6 2018

The European Commission has published the Draft Regulation amending Regulation (EC) No 8472000 as regards the definition of the concept 'similar

No State Law Remedies for Failure to Comply with BPCIA Notice
  • McDermott Will & Emery
  • USA
  • January 25 2018

On remand from the Supreme Court of the United States, the US Court of Appeals for the Federal Circuit held that under the Biologics Price

As Congress Struggles With ACA Repeal, Trump Administration Moves Forward With Regulatory Reform
  • Skadden Arps Slate Meagher & Flom LLP
  • USA
  • January 23 2018

The Trump administration and Republican-led Congress spent substantial time and political capital in 2017 on efforts to repeal and replace the

CAFC and SCOTUS Take First Look at Provisions of BPCIA in Amgen v. Sandoz
  • Finnegan, Henderson, Farabow, Garrett & Dunner LLP
  • USA
  • January 12 2018

In Amgen Inc. v. Sandoz Inc., 794 F.3d 1347 (Fed. Cir. 2015), the CAFC affirmed the district court’s interpretation of the “information exchange”

Sandoz v Amgen: An update
  • Bristows LLP
  • USA
  • January 9 2018

In our most recent publication, the Bristows' Biotech Review (Page 3), we reported on the US Supreme Court decision which, at the time, was the latest

The Highs Celebrating the Ten Best Prescription DrugMedical Device Decisions of 2017
  • Reed Smith LLP
  • USA
  • December 28 2017

Ending the year on a high note is one thing that the blog tries to do - with the top ten drugdevice product liability decisions of the year

Guest Post: Christmas Came Early on December 8 - Favorable Developments in Fosamax & Accutane Litigation
  • Reed Smith LLP
  • USA
  • December 14 2017

This guest post is by Kevin Hara, an associate at Reed Smith and relatively frequent contributor to the Blog. Here, he discusses two recent favorable

Forum Non Conveniens and Choice of Law - Issues Post BMS
  • Dechert LLP
  • USA
  • November 20 2017

Interestingly, it's a case that is almost a year old that has us thinking about litigation tourism post Bristol-Myers Squibb Co. v. Superior Court

Inside the Courts - An Update From Skadden Securities Litigators
  • Skadden Arps Slate Meagher & Flom LLP
  • USA
  • November 5 2017

Judge Patti B. Saris denied the Bank of New York Mellon’s (BNY Mellon) motion to strike putative class representative Ashby Henderson. BNY Mellon

Amgen and Genentech Break New Ground in Avastin Biosimilar Dispute
  • Patterson Belknap Webb & Tyler LLP
  • USA
  • October 26 2017

Amgen and Genentech have become embroiled in a novel procedural dispute relating to Mvasi, Amgen’s biosimilar of Genentech’s Avastin (bevacizumab). On